Amundi Intra Cellular Therapies, Inc. Transaction History
Amundi
- $264 Billion
- Q3 2024
A detailed history of Amundi transactions in Intra Cellular Therapies, Inc. stock. As of the latest transaction made, Amundi holds 2,935 shares of ITCI stock, worth $372,803. This represents 0.0% of its overall portfolio holdings.
Number of Shares
2,935Holding current value
$372,803% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding ITCI
# of Institutions
381Shares Held
84MCall Options Held
319KPut Options Held
143K-
Vanguard Group Inc Valley Forge, PA9.63MShares$1.22 Billion0.01% of portfolio
-
Black Rock Inc. New York, NY6.32MShares$803 Million0.01% of portfolio
-
Jpmorgan Chase & CO New York, NY5.29MShares$671 Million0.03% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT3.85MShares$489 Million1.4% of portfolio
-
Avoro Capital Advisors LLC New York, NY3.05MShares$387 Million3.36% of portfolio
About Intra-Cellular Therapies, Inc.
- Ticker ITCI
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 94,401,696
- Market Cap $12B
- Description
- Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in dev...